Ruxolitinib (Opzelura) Cream for Vitiligo

Ruxolitinib is a medication used to manage and treat myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease.

Recently the FDA has approved Ruxolitinib (Opzelura) as the first at-home treatment for non-segmental vitiligo, a condition that causes lighter patches on the skin. Previously used for conditions like those listed above and atopic dermatitis, Ruxolitinib works by calming down the immune system, encouraging new skin cell growth, and bringing back pigment to affected areas. Using this topical lotion twice daily has shown to help even out skin tone. Some side effects like acne, redness, and itching has been observed for a small number of patients but the treatment is still very promising. Further studies will be needed to fully understand how effective it can really be and as always monitor safety.

Vitiligo is a persistent autoimmune condition characterized by white patches on the skin due to a decrease in functional melanocytes, resulting in prominent and often disfiguring lesions. Its prevalence varies globally, affecting between 0.5% to 2% of the world's population, with higher rates observed in regions like India (8.8%) and Mexico (2.6–4%). Both genetic predisposition and environmental factors contribute to its development, impacting individuals of all skin types and genders equally. Initial lesions may appear faint and depigmented, potentially accompanied by itching and heightened sensitivity to sun exposure. While it can manifest anywhere on the body, common areas include the face, hands, and genital regions.